source
- Analyst warns AstraZeneca-BMS merger could spark regulatory hurdles and job cutsAngus Liu writes an editorial warning that talks of a merger between AstraZeneca and Bristol Myers Squibb could create more problems than benefits. He notes that the two companies have only discuss…
- Analysts Question Potential AstraZeneca-Bristol Myers MegamergerAnalysts are scrutinizing a recent report that suggests AstraZeneca could merge with Bristol Myers Squibb. The proposed megamerger has sparked a series of questions about strategic fit and executio…